Article

Glaucoma 360 panelist shares industry update on new drugs, drops

Conferences|GLAUCOMA 360

Ellie Chabi, MD, Therapeutic Area Head for Glaucoma & Neuroprotection and Lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, provides an update on its glaucoma pipeline.

Ellie Chabi, MD, is Therapeutic Area Head for Glaucoma & Neuroprotection, Lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, shares insights from the industry panel discussion, "Drugs and Drops" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Related Content
SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension
November 19th 2024

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Managing mental health in glaucoma
October 17th 2024

Managing mental health in glaucoma

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Ripple Therapeutics and AbbVie collaborate in development of RTC-620 for IOP reduction in patients with open-angle glaucoma
September 19th 2024

Ripple Therapeutics and AbbVie collaborate in development of RTC-620 for IOP reduction in patients with open-angle glaucoma

Iantrek announces 1-year clinical results of its bio-interventional technology for uveoscleral outflow enhancement in open-angle glaucoma patients
September 17th 2024

Iantrek announces 1-year clinical results of its bio-interventional technology for uveoscleral outflow enhancement in open-angle glaucoma patients

© 2024 MJH Life Sciences

All rights reserved.